Is There A Consensus Regarding Clinically Relevant Non-Inferiority Margins Used For Key Oncology Endpoints In Non-Inferiority Oncology Trials?
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1545
https://www.valueinhealthjournal.com/article/S1098-3015(18)31851-5/fulltext
Section Title :
Section Order :
777
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31851-5&doi=10.1016/j.jval.2018.04.1545